BioStock: Completed recruitment in RhoVac’s phase IIb trial

The covid-19 pandemic came as an unwelcome guest for many drug developers around the world, resulting in delayed and discontinued studies. Lund-based RhoVac is one of the companies that has managed to parry the pandemic reasonably well and can now report that the recruitment for the phase IIb study BRaVac has been completed. The study results are expected by the middle of next year.

Read the full article at biostock.se:

https://www.biostock.se/en/2021/09/completed-recruitment-in-rhovacs-phase-iib-trial/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se